Correlation between Serum Fatty Acid Binding Protein 4 (FABP4) Levels and Cardiac Function in Patients with Thalassemia Major.
Journal
Disease markers
ISSN: 1875-8630
Titre abrégé: Dis Markers
Pays: United States
ID NLM: 8604127
Informations de publication
Date de publication:
2021
2021
Historique:
received:
24
04
2021
revised:
10
10
2021
accepted:
04
12
2021
entrez:
6
1
2022
pubmed:
7
1
2022
medline:
2
4
2022
Statut:
epublish
Résumé
Patients with thalassemia major may suffer from complications due to iron overload. It has been suggested that several adipokines may play a potential role in the development of complications in thalassemia. Fatty acid-binding protein 4 (FABP4) is one of the adipokines, bridging several aspects of metabolic and inflammatory pathways. Little is known about the relationship between this adipokine and cardiac and liver function, especially in patients with thalassemia major. This study is aimed at determining serum FABP4 levels in patients with thalassemia major and whether its concentration correlated with serum ferritin levels, as well as cardiac and liver function. Thalassemia major outpatients ( The mean age was 21.9 ± 8.0 years. A negative and weak correlation between serum ferritin and FABP4 was observed ( Serum FABP4 correlated with serum ferritin and cardiac function in patients with thalassemia major. FABP4 may be a potential clinical biomarker for cardiac dysfunction via metabolic and inflammatory pathways due to iron accumulation and toxicity in patients with thalassemia major.
Sections du résumé
BACKGROUND
BACKGROUND
Patients with thalassemia major may suffer from complications due to iron overload. It has been suggested that several adipokines may play a potential role in the development of complications in thalassemia. Fatty acid-binding protein 4 (FABP4) is one of the adipokines, bridging several aspects of metabolic and inflammatory pathways. Little is known about the relationship between this adipokine and cardiac and liver function, especially in patients with thalassemia major.
AIMS
OBJECTIVE
This study is aimed at determining serum FABP4 levels in patients with thalassemia major and whether its concentration correlated with serum ferritin levels, as well as cardiac and liver function.
METHODS
METHODS
Thalassemia major outpatients (
RESULTS
RESULTS
The mean age was 21.9 ± 8.0 years. A negative and weak correlation between serum ferritin and FABP4 was observed (
CONCLUSIONS
CONCLUSIONS
Serum FABP4 correlated with serum ferritin and cardiac function in patients with thalassemia major. FABP4 may be a potential clinical biomarker for cardiac dysfunction via metabolic and inflammatory pathways due to iron accumulation and toxicity in patients with thalassemia major.
Identifiants
pubmed: 34987673
doi: 10.1155/2021/5130628
pmc: PMC8723846
doi:
Substances chimiques
FABP4 protein, human
0
Fatty Acid-Binding Proteins
0
Ferritins
9007-73-2
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
5130628Informations de copyright
Copyright © 2021 Pandji I. Fianza et al.
Déclaration de conflit d'intérêts
The authors declare that there are no conflicts of interest.
Références
Nat Rev Drug Discov. 2008 Jun;7(6):489-503
pubmed: 18511927
Clin Chim Acta. 2005 Feb;352(1-2):183-90
pubmed: 15653113
World J Gastroenterol. 2012 Sep 14;18(34):4651-8
pubmed: 23002334
Clin Cardiol. 2009 Jun;32(6):E55-9
pubmed: 18412144
BMC Cardiovasc Disord. 2019 Jun 24;19(1):153
pubmed: 31234795
Hemoglobin. 2011;35(1):67-79
pubmed: 21250883
Eur J Haematol. 2015 Sep;95(3):244-53
pubmed: 25418187
Cardiovasc Diabetol. 2014 Aug 21;13:126
pubmed: 25142635
J Lipid Res. 2019 Apr;60(4):734-740
pubmed: 30705117
Biomed Res Int. 2014;2014:261761
pubmed: 24812610
Int J Neonatal Screen. 2019 Mar 20;5(1):16
pubmed: 33072976
Nat Rev Endocrinol. 2015 Oct;11(10):592-605
pubmed: 26260145
Int J Inflam. 2011;2011:642612
pubmed: 22121495
J Thorac Dis. 2016 Sep;8(9):E928-E931
pubmed: 27747028
Indian J Med Res. 2011 Oct;134:498-506
pubmed: 22089614
Indian J Clin Biochem. 2014 Jul;29(3):298-305
pubmed: 24966477
Can J Cardiol. 2009 Apr;25(4):213-8
pubmed: 19340344
J Am Soc Echocardiogr. 2016 Apr;29(4):277-314
pubmed: 27037982
Stroke. 2017 Jun;48(6):1531-1538
pubmed: 28487339
Hemoglobin. 2009;33 Suppl 1:S37-45
pubmed: 20001631
Cardiovasc Diabetol. 2013 May 04;12:72
pubmed: 23642261
Scand J Clin Lab Invest. 2014 Jun;74(4):306-11
pubmed: 24564631
Blood Transfus. 2012 Oct;10(4):411-22
pubmed: 22790257
J Clin Invest. 2019 Feb 25;129(4):1566-1580
pubmed: 30830876
Indian J Hematol Blood Transfus. 2017 Jun;33(2):228-234
pubmed: 28596656
Clin Exp Med. 2016 Aug;16(3):345-50
pubmed: 26052040
J Am Soc Echocardiogr. 2005 Dec;18(12):1440-63
pubmed: 16376782
Hematology Am Soc Hematol Educ Program. 2017 Dec 8;2017(1):265-271
pubmed: 29222265
Biosci Rep. 2016 Jan 28;36(1):e00302
pubmed: 26823558
J Cardiovasc Med (Hagerstown). 2008 May;9(5):515-25
pubmed: 18404006
N Engl J Med. 2005 Sep 15;353(11):1135-46
pubmed: 16162884
Mediterr J Hematol Infect Dis. 2017 Feb 20;9(1):e2017018
pubmed: 28293406
Circulation. 2013 Jul 16;128(3):281-308
pubmed: 23775258
J Res Med Sci. 2010 May;15(3):150-4
pubmed: 21526074
Acta Haematol. 2010;124(4):191-6
pubmed: 21042009
Hemoglobin. 2018 Jan;42(1):68-71
pubmed: 29633668
Mediators Inflamm. 2015;2015:516740
pubmed: 25878400
Int J Hematol. 2008 Jul;88(1):7-15
pubmed: 18594779
Int J Hematol. 2002 Oct;76(3):219-28
pubmed: 12416732
Int J Endocrinol. 2016;2016:6218437
pubmed: 27956899
J Cardiovasc Med (Hagerstown). 2019 May;20(5):284-289
pubmed: 30865135
Clin Med Insights Cardiol. 2015 Feb 02;8(Suppl 3):23-33
pubmed: 25674026
Iran J Ped Hematol Oncol. 2013;3(2):59-63
pubmed: 24575271
J Atheroscler Thromb. 2019 Mar 1;26(3):216-232
pubmed: 30726793
Br J Haematol. 2015 Jul;170(1):15-28
pubmed: 25765344
Ann Hematol. 2002 Sep;81(9):543-7
pubmed: 12373360
Am J Cardiol. 2008 Jul 1;102(1):70-6
pubmed: 18572038